All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.   View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EHA-SWG 2017 | Rare Lymphomas: Bispecific antibodies (BITES)

Mar 24, 2017


On March 12th, at the EHA-SWG Rare Lymphomas Scientific Meeting 2017 in Barcelona, Spain, Marie José Kersten chaired a scientific session on ‘Fighting Lymphoma with T-cells’. The second presentation of this session was given by Andreas Viardot, from the University Hospital, Ulm, Germany, on the topic of ‘Bispecific Antibodies’. Below are the key highlights from this presentation:

  • Bispecific antibodies are a diverse group of engineered molecules which combine two or more monoclonal antibody variable regions
  • In cancer, Bispecific T-cell Engagers (BiTEs) can work by recruiting a T-cell to a cancer cell to bring about tumor lysis through T-cell activation
  • Blinatumomab (CD19xCD3) has recently been given FDA and EMA approval in R/R Acute Lymphoblastic Leukemia

  • Treatment typically requires a constant level of antibody to be maintained in the blood, therefore constant IV infusion for a sustained period of time is necessary
  • Bispecific antibody treatment can result in early CRS, which transiently spikes; can be quickly mitigated by reducing dose due to the antibody’s short half-life in addition to other methods

  • Recent phase I study results in NHL which treated patients with continuous IV blinatumomab (CD19xCD3) for 4–8 weeks

  • Phase II study in R/R DLBCL: ITT ORR = 36%, CR = 16%, PR = 20%

  • Potential new strategies for improving BiTEs in lymphoma
    • New CNS mitigation strategies
    • Modifying the sequence of treatment i.e. pre-conditioning or alternating BiTE and chemotherapy
    • Combining BiTE therapy with checkpoint inhibitors (ongoing trials)
  • A Newer range of CD20xCD3 antibodies are currently being trialed in lymphoma:

  • Conclusions:

References

Your opinion matters

Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?